长江健康(002435) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 873,535,602.23, a decrease of 3.52% compared to CNY 905,405,104.96 in the same period last year[5] - Net profit attributable to shareholders was CNY 60,141,015.34, down 3.18% from CNY 62,117,583.39 year-on-year[5] - The net profit excluding non-recurring gains and losses increased by 36.44% to CNY 53,752,528.72 from CNY 39,396,380.55 in the previous year[5] - Total revenue for Q1 2023 was CNY 873,535,602.23, a decrease of 3.7% compared to CNY 905,405,104.96 in Q1 2022[19] - Net profit for Q1 2023 was CNY 59,052,807.21, an increase of 3.5% from CNY 57,058,225.75 in Q1 2022[20] - The total comprehensive income attributable to the parent company was ¥59,653,332.37, down from ¥61,951,832.05, reflecting a decline of 3.71%[21] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 4,688,490.14, a significant decline of 97.41% compared to CNY 181,228,927.13 in the same period last year[5] - Operating cash flow for Q1 2023 was ¥4,688,490.14, significantly lower than ¥181,228,927.13 in the same period last year, indicating a decrease of 97.42%[23] - Cash and cash equivalents at the end of Q1 2023 were CNY 2,491,636,136.31, up from CNY 1,680,084,001.51 at the beginning of the year[16] - Cash and cash equivalents at the end of Q1 2023 increased to ¥2,401,904,913.35 from ¥1,714,061,391.05, representing a rise of 40.06%[24] - Cash inflow from operating activities totaled ¥988,161,809.86, down 42.09% from ¥1,708,388,783.31 in Q1 2022[23] - Cash outflow from operating activities was ¥983,473,319.72, a decrease of 35.69% compared to ¥1,527,159,856.18 in the previous year[23] - Investment activities generated a net cash inflow of ¥363,389,856.94, contrasting with a net outflow of ¥271,172,451.88 in Q1 2022[23] - Financing activities produced a net cash inflow of ¥444,881,419.92, compared to ¥114,403,672.52 in the same quarter last year, marking an increase of 288.06%[23] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 7,764,956,292.55, reflecting a growth of 5.33% from CNY 7,371,749,936.56 at the end of the previous year[5] - Total assets as of the end of Q1 2023 were CNY 7,764,956,292.55, compared to CNY 7,371,749,936.56 at the beginning of the year[17] - Total liabilities increased to CNY 3,129,755,867.45 from CNY 2,721,908,162.82, an increase of 15.0%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 50.124 million[12] - The largest shareholder, Changjiang Runfa Group, holds 38.08% of shares, amounting to 470,667,365 shares, with 289,334,000 shares pledged[12] - The second-largest shareholder, Zhongshan Songde Zhangjiagang Free Trade Zone Pharmaceutical Industry Equity Investment Enterprise, holds 9.84% of shares, totaling 121,607,997 shares, with 72,033,898 shares frozen[12] - The top ten shareholders include several entities with significant holdings, such as Dongwu Venture Capital with 7.67% (94,830,788 shares) and Huazhong Asset Management with 2.14% (26,448,671 shares)[12] - The company has not disclosed any participation in margin trading by the top ten shareholders[13] - The total number of preferred shareholders is zero, indicating no preferred shares outstanding[14] Government Support and Initiatives - The company received government subsidies totaling CNY 5,753,740.57, mainly from fiscal support and rewards[6] - The company is focusing on market expansion through participation in national drug procurement initiatives[14] - The company’s subsidiary, Hainan Hailing Chemical Pharmaceutical Co., participated in the eighth batch of national centralized drug procurement and is expected to be selected for two products[14] - The company reported that it has passed the consistency evaluation for two injectable drugs, which are expected to be included in the centralized procurement[14] Expenses - Total operating costs for Q1 2023 were CNY 792,274,243.76, down 7.0% from CNY 852,360,005.87 in the previous year[20] - The company reported a decrease in sales expenses to CNY 183,732,085.40 from CNY 204,111,580.72, a reduction of 10.0%[20] - Research and development expenses for Q1 2023 were CNY 10,056,677.28, down from CNY 11,527,938.07, a decrease of 12.8%[20] Return on Equity - The weighted average return on equity was 1.33%, slightly down from 1.37% in the previous year[5] - The basic and diluted earnings per share for Q1 2023 were both ¥0.0487, slightly down from ¥0.0503 in Q1 2022[21]